In mice, angiotensin II treatment—first described in 200032—has become the most popular model for AAA/AAD, used in a wide range of treatment regimens with up to 12 weeks of angiotensin II exposure and with different genetic backgrounds, mainly based on ApoE deficiency33. The gene discussed is APOE; the disease is triple-A syndrome.